SK286029B6 - Farmaceutický prostriedok a jeho použitie - Google Patents

Farmaceutický prostriedok a jeho použitie Download PDF

Info

Publication number
SK286029B6
SK286029B6 SK1792-99A SK179299A SK286029B6 SK 286029 B6 SK286029 B6 SK 286029B6 SK 179299 A SK179299 A SK 179299A SK 286029 B6 SK286029 B6 SK 286029B6
Authority
SK
Slovakia
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
metformin
acceptable form
Prior art date
Application number
SK1792-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK179299A3 (en
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286029(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SK179299A3 publication Critical patent/SK179299A3/sk
Publication of SK286029B6 publication Critical patent/SK286029B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1792-99A 1997-06-18 1998-06-15 Farmaceutický prostriedok a jeho použitie SK286029B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003690 WO1998057634A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Publications (2)

Publication Number Publication Date
SK179299A3 SK179299A3 (en) 2000-11-07
SK286029B6 true SK286029B6 (sk) 2008-01-07

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1792-99A SK286029B6 (sk) 1997-06-18 1998-06-15 Farmaceutický prostriedok a jeho použitie

Country Status (39)

Country Link
US (3) US20060100247A1 (es)
EP (2) EP1787646A3 (es)
JP (1) JP2002504137A (es)
KR (2) KR20060105005A (es)
CN (2) CN1230171C (es)
AP (1) AP1279A (es)
AR (2) AR012998A1 (es)
AT (1) ATE355840T1 (es)
AU (1) AU8539398A (es)
BG (2) BG64818B1 (es)
BR (1) BR9810172A (es)
CA (1) CA2294582C (es)
CY (2) CY1107643T1 (es)
CZ (1) CZ298469B6 (es)
DE (2) DE69837261T2 (es)
DK (1) DK0996444T3 (es)
DZ (1) DZ2520A1 (es)
EA (1) EA003144B1 (es)
ES (1) ES2284212T3 (es)
HK (1) HK1028193A1 (es)
ID (1) ID23372A (es)
IL (3) IL133142A0 (es)
IN (1) IN189722B (es)
LU (1) LU91356I2 (es)
MA (1) MA26512A1 (es)
MY (1) MY129897A (es)
NL (1) NL300288I2 (es)
NO (4) NO324993B1 (es)
NZ (1) NZ501260A (es)
OA (1) OA11516A (es)
PE (1) PE83199A1 (es)
PL (2) PL195140B1 (es)
PT (1) PT996444E (es)
SI (1) SI0996444T1 (es)
SK (1) SK286029B6 (es)
TR (1) TR199903057T2 (es)
TW (1) TW565449B (es)
UY (1) UY25049A1 (es)
WO (1) WO1998057634A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2180296C (en) * 1995-07-03 2007-01-09 Yoshio Tsujita Treatment of arteriosclerosis and xanthoma
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
ATE250418T1 (de) 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
CA2389928C (en) 1999-11-03 2010-03-23 Bristol-Myers Squibb Company Method for treating diabetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
WO2001082867A2 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
CA2725833A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
CA2499597C (en) * 2002-09-20 2012-01-17 Unchalee Kositprapa Multistage formulation containing a biguanide and thiazolidindione derivatives
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1588708A4 (en) 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
WO2006011397A1 (ja) * 2004-07-27 2006-02-02 Kowa Company., Ltd. 糖尿病の予防または治療のための薬剤
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
CA2615118A1 (en) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar.gamma. agonist
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
EP2313360B1 (en) * 2008-07-28 2012-09-05 Syddansk Universitet Compounds for the treatment of metabolic diseases
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
MX2013007884A (es) 2011-01-07 2013-09-13 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
CA2860669C (en) 2012-01-06 2022-05-03 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
EA201491335A1 (ru) 2012-01-06 2015-04-30 Элселикс Терапьютикс, Инк. Бигуанидные композиции и способы лечения метаболических расстройств

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
SK72096A3 (en) * 1995-06-06 1997-11-05 Pfizer Indole-2-carboxamides, glycogen phosphorylase inhibitors and pharmauceutical compositions
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
ID23372A (id) 2000-04-20
MA26512A1 (fr) 2004-12-20
NL300288I1 (nl) 2007-11-01
JP2002504137A (ja) 2002-02-05
TW565449B (en) 2003-12-11
AR012995A1 (es) 2000-11-22
EP1787646A2 (en) 2007-05-23
NO996266D0 (no) 1999-12-17
AP1279A (en) 2004-05-20
DZ2520A1 (fr) 2003-02-01
PL195140B1 (pl) 2007-08-31
DE69837261D1 (de) 2007-04-19
IN189722B (es) 2003-04-19
PL195136B1 (pl) 2007-08-31
BR9810172A (pt) 2000-08-08
NO996266L (no) 1999-12-17
PT996444E (pt) 2007-06-08
TR199903057T2 (xx) 2000-04-21
IL133142A0 (en) 2001-03-19
KR100666591B1 (ko) 2007-01-11
CY1107643T1 (el) 2012-01-25
NO20063000L (no) 1999-12-17
CN1114404C (zh) 2003-07-16
CN1429551A (zh) 2003-07-16
CA2294582C (en) 2008-02-12
MY129897A (en) 2007-05-31
NL300288I2 (nl) 2009-06-02
EA003144B1 (ru) 2003-02-27
CN1230171C (zh) 2005-12-07
AP9901719A0 (en) 1999-12-31
EP0996444A1 (en) 2000-05-03
KR20010013844A (ko) 2001-02-26
IL133142A (en) 2006-06-11
EP0996444B1 (en) 2007-03-07
SI0996444T1 (sl) 2007-08-31
BG64818B1 (bg) 2006-05-31
ATE355840T1 (de) 2007-03-15
PL337362A1 (en) 2000-08-14
HK1028193A1 (en) 2001-02-09
US20080090881A1 (en) 2008-04-17
ES2284212T3 (es) 2007-11-01
SK179299A3 (en) 2000-11-07
KR20060105005A (ko) 2006-10-09
CZ9904578A3 (en) 2001-06-13
NO324993B1 (no) 2008-01-14
CY2007018I1 (el) 2012-01-25
AU8539398A (en) 1999-01-04
DK0996444T3 (da) 2007-07-02
LU91356I2 (fr) 2008-01-29
US20060100247A1 (en) 2006-05-11
DE69837261T2 (de) 2007-11-08
NO2008003I2 (no) 2010-06-28
NZ501260A (en) 2002-09-27
WO1998057634A1 (en) 1998-12-23
PE83199A1 (es) 1999-10-22
OA11516A (en) 2004-02-04
EP1787646A3 (en) 2007-10-03
AR012998A1 (es) 2000-11-22
NO20090846L (no) 1999-12-17
EA200000041A1 (ru) 2000-08-28
DE122007000054I1 (de) 2007-12-13
BG104060A (en) 2000-10-31
US20070004780A1 (en) 2007-01-04
BG109398A (bg) 2006-05-31
CZ298469B6 (cs) 2007-10-10
NO2008003I1 (no) 2008-04-21
CA2294582A1 (en) 1998-12-23
NO326958B1 (no) 2009-03-23
CN1260716A (zh) 2000-07-19
IL173650A0 (en) 2006-07-05
UY25049A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
SK286029B6 (sk) Farmaceutický prostriedok a jeho použitie
US20050059706A1 (en) Treatment of diabetes with thiazolidinedione and metformin
CA2296653C (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
SK179399A3 (en) Use of insulin sensitiser and an insulin
US20030187030A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20050054687A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
CA2294385C (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
EP0998291B1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
SK612000A3 (en) Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition
US20040106543A1 (en) Treatment of diabetes with rosiglitazone and insulin
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
AU783539B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
US20030073645A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20110615